Welcome to our dedicated page for Bio Rad Labs SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bio-Rad is a Delaware corporation based in Hercules, California, and its filings offer detailed information on its life science research and clinical diagnostics businesses, financial performance, and material corporate events.
Investors can review current reports on Form 8-K, where Bio-Rad reports items such as quarterly financial results, supplemental earnings presentations, leadership changes, acquisitions, and other significant events. Recent 8-K filings reference the announcement of results for quarters ended June 30 and September 30, the completion of the acquisition of Stilla Technologies, and the appointment of senior executives.
In addition to current reports, users may consult annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed) for more extensive discussion of segment performance in the Life Science and Clinical Diagnostics groups, risk factors, accounting policies, and details on items such as the company’s investment in Sartorius. These filings also describe Bio-Rad’s use of non-GAAP financial measures and provide reconciliations to GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify items such as revenue trends, margin drivers, and notable changes in investments or capital structure. The platform also surfaces insider transaction reports on Form 4 when they are filed, allowing users to track equity transactions by Bio-Rad officers and directors. Together, these tools make it easier to interpret BIO’s SEC filings without reading every line of the underlying documents.
Bio-Rad Laboratories reported Q1 2026 results showing stable sales but a large accounting loss driven by its equity holdings. Net sales were $592.1 million, up slightly from $585.4 million a year earlier, with gross margin steady at 52.3%.
Operating income improved to $34.1 million from $23.7 million, but a $738.2 million loss from changes in fair value of equity securities and a loan receivable, including a $727.7 million holding loss on its Sartorius investment, led to a net loss of $527.1 million versus prior-year net income of $64.0 million.
Cash from operations was $108.1 million, and Bio-Rad ended the quarter with $507.2 million in cash and cash equivalents plus $1,057.5 million in short-term investments. The company repurchased 176,257 Class A shares for $47.8 million and still has $237.1 million available under its 2023 share repurchase program, while carrying $1.2 billion of Senior Notes due 2027 and 2032.
Bio-Rad Laboratories reported first-quarter 2026 net sales of $592.1 million, up 1.1% year over year, but down 4.2% on a currency-neutral basis as both Life Science and Clinical Diagnostics segments faced softer demand.
The company recorded a large GAAP net loss of $527.1 million, or $(19.55) per diluted share, mainly from a $738.2 million loss on the change in fair value of equity securities, including its Sartorius AG investment. On a non-GAAP basis, net income was $50.9 million, or $1.89 per diluted share, down from $2.54 a year earlier, reflecting lower margins and higher adjustments.
Operating cash flow was $108.1 million and free cash flow $78.1 million, both below the prior year, although management highlighted strong cash generation and share repurchases of about 176 thousand shares. Bio-Rad also lowered its full-year 2026 outlook, now expecting non-GAAP currency-neutral revenue between a 3.0% decline and 0.5% growth and a non-GAAP operating margin of roughly 10.0% to 12.0%, down from its prior 12.0% to 12.5% margin range.
Bio-Rad Laboratories EVP and Chief Financial Officer Roop Kalyan Lakkaraju reported routine equity compensation activity. On April 24, 2026, 1,078 shares of Class A common stock were acquired upon vesting of restricted stock units and converted from derivative form.
To cover tax obligations, 420 shares were disposed of through a tax-withholding transaction at $287.84 per share, leaving 2,563.895 Class A shares held directly. The filing also notes 2,156 restricted stock units remaining outstanding and references a prior 4,311-unit RSU grant vesting in four annual installments.
BIO-RAD LABORATORIES, INC. executive vice president and general counsel Courtney C. Enloe reported routine equity compensation activity. On April 24, she acquired 186 shares of Bio-Rad Class A common stock upon the vesting and conversion of restricted stock units, then had 77 shares withheld to cover tax obligations. These transactions increased her direct holdings to 826.777 Class A shares and reduced her restricted stock unit balance to 372 units from an original 744-unit grant scheduled to vest in four equal annual installments.
Bio-Rad Laboratories reported results of its April 21, 2026 annual meeting. Stockholders approved an amended 2017 Incentive Award Plan that increases the shares of common stock reserved for issuance by 335,000 and extends the plan’s expiration to March 18, 2036.
All nominated directors were elected by the required majorities, KPMG LLP was ratified as independent auditor for the year ending December 31, 2026, and executive compensation received majority support in a non-binding advisory vote. A stockholder proposal regarding the company’s dual class capital structure did not receive the required majority approval.
Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through routine equity compensation. On April 21, 2026, 407 restricted stock units vested and were settled into 407 shares of Bio-Rad Class A common stock. Following this settlement, Hinckley directly held 1,215 shares of Class A common stock.
On the same date, he received a new grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. These units will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity. She exercised 407 restricted stock units into 407 shares of Bio-Rad Class A common stock, bringing her direct common stock holdings to 715 shares.
On the same date, she received a new grant of 369 restricted stock units, each representing a right to one share of Class A common stock. These new units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of stockholders, aligning her compensation with future company performance and governance milestones.
Bio-Rad Laboratories director Jeffrey L. Edwards exercised restricted stock units into Bio-Rad Class A common shares and received a new equity award. He acquired 407 shares of Bio-Rad A Common Stock upon vesting of restricted stock units, bringing his direct holdings to 715 shares.
At the same time, 407 Restricted Stock Units were fully converted, leaving no remaining units from that grant. Edwards was also granted 369 new Restricted Stock Units, each representing a contingent right to receive one share of Bio-Rad Class A common stock, vesting 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
BIO-RAD LABORATORIES, INC. director Arnold A. Pinkston reported routine equity compensation activity. He acquired 407 shares of Bio-Rad Class A common stock upon vesting of restricted stock units, bringing his direct common stock holdings to 715 shares after the transaction.
The filing also shows 407 restricted stock units were fully settled, reducing that RSU position to zero. In addition, he received a new grant of 369 restricted stock units, each representing one share of Class A common stock, which will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
The Vanguard Group filed an amended Schedule 13G reporting that it currently beneficially owns 0 shares (0%) of Bio-Rad Laboratories Inc. The filing explains that on January 12, 2026 Vanguard completed an internal realignment and began reporting certain subsidiaries' holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.